Company Introduction

MicroSigX Biotech Diagnostic Limited is a spin-off company from The Chinese University of Hong Kong, founded by a team of world-class clinician-scientists. Our purpose is to transform lives with microbiome diagnostics, with a focus on developing revolutionary non-invasive diagnostic solutions.

Our proprietary fecal microbial testing technology precisely decodes the unique signals of the human microbiome. This breakthrough enables fast, accurate, and cost-effective early detection for a range of major global diseases, including colorectal cancer (CRC), neurodiversity conditions such as autism spectrum disorder and attention deficit hyperactivity disorder (ASD/ADHD), and inflammatory bowel disease (IBD).

Our diagnostics not only facilitate early identification of disease risks but also support timely and effective clinical interventions, significantly improving treatment outcomes. Backed by rigorous clinical validation, a multidisciplinary expert team, and strengths in both research and commercialization, MicroSigX is committed to eliminating uncertainty in medical diagnostics.

We are actively advancing Hong Kong’s role as a global leader in microbiome diagnostics, driving innovation that promotes better health outcomes for people around the world.